QURE - uniQure N.V.
NASDAQ
->
Healthcare
->
Biotechnology
Amsterdam,
Netherlands
Type: Equity
QURE price evolution
QURE
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $241.36 | $229.48 | $513.6 | $153.85 |
| Short term investments | $376.53 | $429.43 | $114.99 | $161.49 |
| Net receivables | $4.19 | $1.64 | $102.56 | $104.79 |
| Inventory | $12.02 | $15.65 | $10.21 | $7.48 |
| Total current assets | $651.85 | $693.63 | $756.96 | $442.64 |
| Long term investments | ||||
| Property, plant & equipment | $75.34 | $76.31 | $79.96 | $82.21 |
| Goodwill & intangible assets | $86.86 | $83.25 | $85.73 | $85.7 |
| Total noncurrent assets | $179.84 | $177.92 | $185.81 | $188.36 |
| Total investments | $376.53 | $429.43 | $114.99 | $161.49 |
| Total assets | $831.69 | $871.55 | $942.77 | $631 |
| Current liabilities | ||||
| Accounts payable | $6.59 | $5.58 | $9.37 | $8.88 |
| Deferred revenue | ||||
| Short long term debt | $8.34 | $7.89 | $7.78 | $7.67 |
| Total current liabilities | $73.67 | $68.61 | $68.36 | $66.34 |
| Long term debt | $524.31 | $514.12 | $503.75 | $134.33 |
| Total noncurrent liabilities | $550.34 | $534.16 | $521.09 | $151.9 |
| Total debt | $532.65 | $522.01 | $511.53 | $142 |
| Total liabilities | $624.02 | $602.77 | $589.45 | $218.23 |
| Shareholders' equity | ||||
| Retained earnings | -$890.41 | -$817.2 | -$727.63 | -$659.16 |
| Other shareholder equity | -$53.55 | -$58.56 | -$52.44 | -$52.49 |
| Total shareholder equity | $207.67 | $268.78 | $353.32 | $412.77 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $241.36 | $228.01 | $556.26 | $244.93 |
| Short term investments | $376.53 | $124.83 | ||
| Net receivables | $4.19 | $102.38 | $58.77 | $6.62 |
| Inventory | $12.02 | $6.92 | ||
| Total current assets | $651.85 | $476.77 | $628.24 | $258.91 |
| Long term investments | $39.98 | $2.75 | ||
| Property, plant & equipment | $75.34 | $83.26 | $69.08 | $58.41 |
| Goodwill & intangible assets | $86.86 | $84.36 | $90.32 | $3.9 |
| Total noncurrent assets | $179.84 | $228.19 | $180.94 | $81.48 |
| Total investments | $376.53 | $164.81 | $2.75 | |
| Total assets | $831.69 | $704.96 | $809.18 | $340.39 |
| Current liabilities | ||||
| Accounts payable | $6.59 | $10.98 | $2.5 | $3.77 |
| Deferred revenue | ||||
| Short long term debt | $8.34 | $8.38 | $5.77 | $5.52 |
| Total current liabilities | $73.67 | $75.92 | $36.76 | $27.33 |
| Long term debt | $524.31 | $102.79 | $129.95 | $66.02 |
| Total noncurrent liabilities | $550.34 | $153.04 | $176.64 | $69.16 |
| Total debt | $532.65 | $142.89 | $135.72 | $71.54 |
| Total liabilities | $624.02 | $228.96 | $213.4 | $96.49 |
| Shareholders' equity | ||||
| Retained earnings | -$890.41 | -$581.93 | -$455.14 | -$784.73 |
| Other shareholder equity | -$53.55 | -$58.29 | -$28.86 | $9.91 |
| Total shareholder equity | $207.67 | $476.01 | $595.78 | $243.91 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.69 | $1.41 | $2.42 | $5.33 |
| Cost of revenue | $8.84 | $1.01 | $1.35 | $2.44 |
| Gross Profit | -$2.15 | $0.4 | $1.07 | $2.89 |
| Operating activities | ||||
| Research & development | $42.62 | $65.4 | $46.04 | $60.81 |
| Selling, general & administrative | $17.49 | $18.07 | $21.18 | $17.85 |
| Total operating expenses | $59.6 | $82.28 | $67.45 | $78.87 |
| Operating income | -$61.75 | -$81.88 | -$66.38 | -$75.98 |
| Income from continuing operations | ||||
| EBIT | -$54.46 | -$74.2 | -$61.47 | -$74.87 |
| Income tax expense | $3.03 | -$0.07 | $0.16 | -$1.21 |
| Interest expense | $15.71 | $15.44 | $6.84 | $3.56 |
| Net income | ||||
| Net income | -$73.21 | -$89.57 | -$68.47 | -$77.23 |
| Income (for common shares) | -$73.21 | -$89.57 | -$68.47 | -$77.23 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.84 | $106.48 | $524 | $37.51 |
| Cost of revenue | $13.63 | $3.34 | $24.98 | |
| Gross Profit | $2.21 | $103.14 | $499.03 | $37.51 |
| Operating activities | ||||
| Research & development | $214.86 | $197.59 | $143.55 | $122.4 |
| Selling, general & administrative | $74.59 | $55.06 | $56.29 | $42.58 |
| Total operating expenses | $285.09 | $253.47 | $200.71 | $166.28 |
| Operating income | -$282.87 | -$150.33 | $298.31 | -$128.77 |
| Income from continuing operations | ||||
| EBIT | -$265 | -$116.56 | $340.28 | -$137.62 |
| Income tax expense | $1.92 | -$1.47 | $3.22 | -$16.42 |
| Interest expense | $41.56 | $11.7 | $7.47 | $3.83 |
| Net income | ||||
| Net income | -$308.48 | -$126.79 | $329.59 | -$125.02 |
| Income (for common shares) | -$308.48 | -$126.79 | $329.59 | -$125.02 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$73.21 | -$89.57 | -$68.47 | -$77.23 |
| Operating activities | ||||
| Depreciation | $4.19 | $2.6 | $2.59 | $2.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.04 | $11.1 | $8.89 | $8.06 |
| Total cash flows from operations | -$49.54 | $38.91 | -$57 | -$78.3 |
| Investing activities | ||||
| Capital expenditures | -$2.04 | -$1.7 | -$1.07 | -$2.34 |
| Investments | $61.6 | -$312.37 | $46.9 | $5.33 |
| Total cash flows from investing | $59.56 | -$314.07 | $45.83 | $2.99 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | $0.06 | $0.07 | $0.13 |
| Net borrowings | $370.06 | |||
| Total cash flows from financing | $0.05 | -$7.59 | $370.14 | $0.13 |
| Effect of exchange rate | $1.84 | -$1.39 | $0.78 | $1.03 |
| Change in cash and equivalents | $11.91 | -$284.14 | $359.75 | -$74.15 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$308.48 | -$126.79 | $329.59 | -$125.02 |
| Operating activities | ||||
| Depreciation | $11.9 | $8.54 | $7.3 | $10.65 |
| Business acquisitions & disposals | -$1.9 | -$49.95 | ||
| Stock-based compensation | $35.09 | $34.2 | $25.64 | $21.83 |
| Total cash flows from operations | -$145.93 | -$145.06 | $287.96 | -$134.83 |
| Investing activities | ||||
| Capital expenditures | -$7.15 | -$17.69 | -$17.44 | -$7.27 |
| Investments | -$198.53 | -$163.15 | ||
| Total cash flows from investing | -$205.69 | -$182.73 | -$67.39 | -$9.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.31 | $1.45 | $32.36 | $7.44 |
| Net borrowings | $370.06 | $62.49 | ||
| Total cash flows from financing | $362.72 | $1.45 | $94.86 | $7.44 |
| Effect of exchange rate | $2.27 | -$1.83 | -$3.76 | $3.82 |
| Change in cash and equivalents | $13.37 | -$328.18 | $311.67 | -$133.05 |
News
Fundamentals
| Market cap | $224.82M |
|---|---|
| Enterprise value | $516.11M |
| Shares outstanding | 47.83M |
| Revenue | $15.84M |
|---|---|
| EBITDA | -$253.10M |
| EBIT | -$265.00M |
| Net Income | -$308.48M |
| Revenue Q/Q | -93.49% |
| Revenue Y/Y | -85.12% |
| P/E ratio | -0.73 |
|---|---|
| EV/Sales | 32.58 |
| EV/EBITDA | -2.04 |
| EV/EBIT | -1.95 |
| P/S ratio | 14.19 |
| P/B ratio | 0.86 |
| Book/Share | 5.46 |
| Cash/Share | 5.05 |
| EPS | -$6.45 |
|---|---|
| ROA | -37.65% |
| ROE | -99.31% |
| Debt/Equity | 3.00 |
|---|---|
| Net debt/EBITDA | -1.51 |
| Current ratio | 8.85 |
| Quick ratio | 8.68 |